19181-69-2 Usage
Uses
Used in Organic Synthesis:
6-hydroxy-3-Methyl-3,4-dihydroquinazolin-4-one is used as a key intermediate in the synthesis of complex organic molecules. Its unique structure allows for the formation of diverse chemical entities, making it a valuable component in the creation of novel compounds with potential applications in various fields.
Used in Medicinal Chemistry:
In the pharmaceutical industry, 6-hydroxy-3-Methyl-3,4-dihydroquinazolin-4-one is utilized as a building block for the synthesis of bioactive compounds. Its incorporation into drug molecules can enhance their therapeutic effects, leading to the development of new medications with improved efficacy and safety profiles.
Used in the Treatment of Neurological Disorders:
6-hydroxy-3-Methyl-3,4-dihydroquinazolin-4-one has been studied for its potential application in the treatment of neurological disorders. Its pharmacological properties suggest that it may have neuroprotective effects, making it a promising candidate for further research and development in this area.
Used in the Development of Pharmaceuticals:
6-hydroxy-3-Methyl-3,4-dihydroquinazolin-4-one's potential as a pharmaceutical agent is being explored due to its ability to be incorporated into drug molecules. This can lead to the creation of new medications with targeted therapeutic effects, particularly for the treatment of various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 19181-69-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,1,8 and 1 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 19181-69:
(7*1)+(6*9)+(5*1)+(4*8)+(3*1)+(2*6)+(1*9)=122
122 % 10 = 2
So 19181-69-2 is a valid CAS Registry Number.
19181-69-2Relevant academic research and scientific papers
NEW METHYLQUINAZOLINONE DERIVATIVES
-
Page/Page column 23, (2021/06/22)
The invention provides a novel compound having the general formula (I) (I), or a pharmaceutically acceptable salt thereof. The compound of formula (I) can be used as a medicament.
NEW BRAF INHIBITORS AS PARADOX BREAKERS
-
Page/Page column 34, (2021/06/22)
The invention provides a novel compound having the general formula (I) (I) wherein R1-R3 and X are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
LACTAM COMPOUND DERIVATIVE AND APPLICATION THEREOF
-
Paragraph 0075, (2018/10/15)
The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing or treating schizop
QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
-
Page/Page column 31, (2008/06/13)
The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
